Indications
Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist.
Composition
- Active substance
- fluticasone furoate, umeclidinium bromide, vilanterol trifenatate
- International name (INN)
- fluticasone furoate;umeclidinium;vilanterol
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Trelegy Ellipta
- Active substance
- fluticasone furoate, umeclidinium bromide, vilanterol trifenatate
- ATC code
- R03AL08
- Group
- Respiratory system
- Therapeutic area